Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBA of Linezolid and Fluoroquinolones in Pulmonary TB
NCT00396084Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2004
- Primary completion
- Nov 2007
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of linezolid, gatifloxacin, levofloxacin and moxifloxacin in pulmonary tuberculosis (TB) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Early Bactericidal Activity Days 0 to 2, Extended Early Bactericidal Activity Days 2 to 7 and 1 more. Started Feb 2004; status: completed.
02
Drugs
linezolidgatifloxacinlevofloxacinmoxifloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT00396084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396084.